Li Dan, Huang Shaoping, Wang Xueying, Yang Lin, Song Tingting
Department of Pediatrics, The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Fifth Department of Pediatrics, Northwest Women's and Children's Hospital, Xi'an, China.
Front Neurol. 2022 Jul 27;13:924057. doi: 10.3389/fneur.2022.924057. eCollection 2022.
To observe the clinical effect and adverse reactions of perampanel in the treatment of epilepsy in children.
A retrospective analysis was performed on 83 children with epilepsy who were treated with perampanel in the Department of Pediatric Neurology, Second Affiliated Hospital of Xi'an Jiaotong University from April to August 2021. The treatment status, prognosis and adverse reactions were followed up. The effective rates of different age groups, different seizure types and epilepsy syndromes, and different treatment methods were statistically analyzed. The effective rate and adverse reactions of all patients were statistically analyzed.
The overall effective rate of perampanel in the treatment of epilepsy was 62.03%, and there was no significant difference in the effective rate of perampanel in the treatment of epilepsy in patients of different ages ( > 0.05). The effective rates of perampanel in the treatment of focal seizures and generalized seizures were 60.38% and 65.38%, and the effective rates of benign childhood epilepsy with centrotemporal spikes (BECT), BECT combined with electrical status epilepticus during sleep (ESES) and frontal lobe epilepsy (FLE) were 88.89, 72.73, and 66.67%. The effective rates of monotherapy and combination therapy were 88.88 and 58.57%, respectively. The above statistical differences were not statistically significant ( > 0.05). In addition, the adverse reaction rate of perampanel treatment was 16.45%, including irritability, drowsiness, dizziness, nausea, vomiting and abnormal liver function.
Perampanel has a high efficiency and controllable adverse reactions in the treatment of childhood epilepsy. This drug can be used as a reliable choice for long-term use in the treatment of epilepsy in children.
观察吡仑帕奈治疗儿童癫痫的临床疗效及不良反应。
对2021年4月至8月在西安交通大学第二附属医院小儿神经内科接受吡仑帕奈治疗的83例癫痫患儿进行回顾性分析。对治疗情况、预后及不良反应进行随访。对不同年龄组、不同发作类型及癫痫综合征、不同治疗方法的有效率进行统计分析。对所有患者的有效率及不良反应进行统计分析。
吡仑帕奈治疗癫痫的总有效率为62.03%，不同年龄患者吡仑帕奈治疗癫痫的有效率差异无统计学意义（>0.05）。吡仑帕奈治疗局灶性发作和全身性发作的有效率分别为60.38%和65.38%，治疗伴有中央颞区棘波的儿童良性癫痫（BECT）、BECT合并睡眠中癫痫性电持续状态（ESES）及额叶癫痫（FLE）的有效率分别为88.89%、72.73%和66.67%。单药治疗和联合治疗的有效率分别为88.88%和58.57%。上述统计差异均无统计学意义（>0.05）。此外，吡仑帕奈治疗的不良反应发生率为16.45%，包括烦躁、嗜睡、头晕、恶心、呕吐及肝功能异常。
吡仑帕奈治疗儿童癫痫疗效高且不良反应可控。该药可作为儿童癫痫长期治疗的可靠选择。
